Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Last Updated: June 27, 2022

Details for New Drug Application (NDA): 211527

✉ Email this page to a colleague

« Back to Dashboard

NDA 211527 describes AKLIEF, which is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the AKLIEF profile page.

The generic ingredient in AKLIEF is trifarotene. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the trifarotene profile page.
Summary for 211527
Applicant:Galderma Labs Lp
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 211527
Generic Entry Date for 211527*:
Constraining patent/regulatory exclusivity:

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 211527
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
AKLIEF trifarotene CREAM;TOPICAL 211527 NDA Galderma Laboratories, L.P. 0299-5935 0299-5935-02 1 TUBE in 1 BLISTER PACK (0299-5935-02) > 2 g in 1 TUBE
AKLIEF trifarotene CREAM;TOPICAL 211527 NDA Galderma Laboratories, L.P. 0299-5935 0299-5935-30 1 BOTTLE, PUMP in 1 CARTON (0299-5935-30) > 30 g in 1 BOTTLE, PUMP

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CREAM;TOPICALStrength0.005%
Approval Date:Oct 4, 2019TE:RLD:Yes
Regulatory Exclusivity Expiration:Oct 4, 2024
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:See Plans and PricingPatent Expiration:Oct 1, 2026Product Flag?YSubstance Flag?YDelist Request?
Patent:See Plans and PricingPatent Expiration:Dec 21, 2025Product Flag?Substance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.